Loading…
Eris Lifesciences (ERIS)₹1,262+0.71%Pharmaceuticals
At the end of the Sep 2026 quarter, Eris Lifesciences' shareholders were: promoters 54.75%, FIIs 5.76%, DIIs 20.25%, public 19.24%. Promoter holding is up 0.60 percentage points from 54.15% a quarter earlier. FII holding is down 1.47 percentage points from 7.23% a year earlier. 16.76% of promoter shares were pledged. It had 49,033 shareholders.
As of · Company filings (shareholding pattern)
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 54.91% | 54.91% | 54.89% | 54.88% | 54.87% | 54.86% | 54.84% | 54.86% | 54.86% | 53.93% | 54.15% | 54.75% |
| FIIs | 13.15% | 14.29% | 14.61% | 8.03% | 8.38% | 8.45% | 8.41% | 7.23% | 6.87% | 6.41% | 5.78% | 5.76% |
| DIIs | 14.61% | 15.69% | 16.29% | 18.70% | 18.13% | 18.13% | 18.24% | 19.42% | 20.37% | 20.41% | 20.77% | 20.25% |
| Public | 17.33% | 15.11% | 14.21% | 18.39% | 18.62% | 18.56% | 18.51% | 18.49% | 17.90% | 19.25% | 19.30% | 19.24% |
| Promoter shares pledged | — | — | — | — | — | — | — | — | — | — | — | 16.76% |
| Number of shareholders | 46,495 | 51,752 | 44,175 | 46,345 | 53,313 | 50,086 | 52,224 | 59,437 | 54,712 | 51,655 | 50,797 | 49,033 |
| Holder | Category | Sep 2026 | Change (pp) |
|---|---|---|---|
| Amit Indubhusan Bakshi | Promoter | 43.00% | +0.62 |
| Lilac Investments Limited | Public | 8.60% | −0.01 |
| Hdfc Small Cap Fund | DII | 8.20% | −0.14 |
| Inderjeet Singh Negi | Promoter | 4.32% | −0.01 |
| Rajendrakumar Rambhai Patel | Promoter | 4.26% | −0.01 |
| Franklin India Small Cap Fund | DII | 3.73% | −0.53 |
| Kaushal Kamleshkumar Shah | Promoter | 3.21% | 0.00 |
| Hetal Rasiklal Shah | Public | 2.10% | 0.00 |
| Bhikhalal Chimanlal Shah | Public | 1.94% | 0.00 |
| Naishadh Vikram Shah | Public | 1.67% | 0.00 |
| Rakesh Shah | Public | 1.41% | −0.01 |
| Uti-Flexi Cap Fund | DII | 1.05% | −0.51 |
| Dsp Small Cap Fund | DII | 1.04% | New |
| Hsbc Mutual Fund - Hsbc Small Cap Fund | DII | 1.02% | 0.00 |
Promoters held 54.75% of Eris Lifesciences at the end of the Sep 2026 quarter, down 0.11 percentage points from 54.86% a year earlier.
In the Sep 2026 quarter, foreign institutional investors (FIIs) held 5.76% (down 0.02 percentage points from 5.78% a quarter earlier) and domestic institutions (DIIs) held 20.25% (down 0.52 percentage points from 20.77% a quarter earlier).
Yes. 16.76% of promoter shares were pledged at the end of the Sep 2026 quarter.
Eris Lifesciences had 49,033 shareholders at the end of the Sep 2026 quarter, against 59,437 a year earlier.
Lilac Investments Limited (Public) held 8.60% at the end of the Sep 2026 quarter, the largest named holding outside the promoter group.